S017 The Quality Improvement and Innovation Symposium
DESCRIPTION
This symposium is directed by members of the AAD's Patient Safety and Quality Committee who are committed to improving Quality Metrics and Outcomes for dermatologic care. The first half of the symposium will feature the AAD's Resident Quality Improvement Award and Innovations in Quality Improvement Award Recipients. The second half of the symposium will feature a summary of the challenges facing dermatology in terms of patient access and will provide insights from an expert group of panelists comprised of dermatologists who are pioneering innovative access projects highlighting the use of technology and algorithms for prioritization of urgent appointment.
LEARNING OBJECTIVES
Demonstrate effective patient access models for scheduling of clinical practice patients
Design interventions to improve patient access in dermatology through innovative scheduling algorithms, implementation of technology, and prioritization of urgency of visits
Discuss ways in which quality improvement can be integrated into clinical care across various practice settings
SCHEDULE
1:00 PM
Introduction to Symposium
Martina J. Porter, MD, FAAD, Ramona Behshad, MD, FAAD
1:05 PM
Innovations in QI Awardee: Creating an Equitable Dermatology Safety Net for Temporarily Disabled Patients: Improving Access, Reducing Readmissions, and Enhancing Patient-Centered Care
Gideon Smith, MD, FAAD
1:25 PM
Introduction of Resident QI Awardees
Joshua L. Owen, MD, PhD, FAAD
1:30 PM
Identifying and Reducing Low-Risk Total Body Skin Exams
Anjani Sheth, MD, MPH, Nikki Trupiano, MD
1:40 PM
Streamline the Screen Time: Improving EMR Efficiency through EPIC Express Lanes
Albert Zhou, MD, PhD
1:50 PM
Optimizing Patient Communication Intake and Triage by EHR-embedded tools to Improve Patient Outcomes and Reduce Physician Burden
Kelly Flanagan, MS
2:00 PM
Implementation of Epic-Compatible Artificial Intelligence Scribing to Reduce Dermatology Resident Burnout
Lauren Banner, MD, Kayla Brockmeyer, MD
2:10 PM
Improving Prevention of Atherosclerotic Cardiovascular Disease in Patients with Psoriasis
David Weiner, MD, MBE
2:20 PM
Improving Dermatologic Health and Hygiene for People Experiencing Homelessness: A Bronx Shelter Quality Improvement Project
Elif Karatas, MD
2:30 PM
Overview of Access and Scheduling Challenges Facing Dermatologists
Martina J. Porter, MD, FAAD
2:55 PM
Introduction of Panelists Pioneering Innovative Workflows to Improve Access
Martina J. Porter, MD, FAAD, Ramona Behshad, MD, FAAD
3:00 PM
Access in the Veterans Health Administration: Implementation of Teledermatology Triage
Joshua L. Owen, MD, PhD, FAAD
3:12 PM
1) Online scheduling module; 2) AI analysis of call volume/sentiment/success rate and; 3) Using AI to review difficult patient's charts to help improve clinic efficiency and improve access
Roman Bronfenbrener, MD, FAAD
3:24 PM
Skin check triage and deferral of appointments
Rita Khodosh, MD, PhD, FAAD
3:36 PM
Panel Discussion and Questions
Ramona Behshad, MD, FAAD, Roman Bronfenbrener, MD, FAAD, Rita Khodosh, MD, PhD, FAAD, Joshua L. Owen, MD, PhD, FAAD
DIRECTOR
Martina J. Porter, MD, FAAD
Beth Israel Deaconess Medical Center & Harvard Medical School
SPEAKERS
Lauren Banner, MD
Ramona Behshad, MD, FAAD
Kayla Brockmeyer, MD
Roman Bronfenbrener, MD, FAAD
Kelly Flanagan, MS
Elif Karatas, MD
Montefiore Medical Center/ Albert Einstein College of Medicine
Richard A. Keller, MD, FAAD
Dermatology Service, Audie Murphy Veterans Administration Hospital
Rita Khodosh, MD, PhD, FAAD
Joshua L. Owen, MD, PhD, FAAD
South Texas Veterans Health Care System / University of Texas Health San Antonio
Anjani Sheth, MD, MPH
Gideon Smith, MD, FAAD
Nikki Trupiano, MD
David Weiner, MD, MBE
Albert Zhou, MD, PhD
DISCLOSURES
Lauren Banner, MD
No financial relationships exist with ineligible companies.
Ramona Behshad, MD, FAAD
Castle Biosciences, Inc – Investigator(Grants/Research Funding);
Kayla Brockmeyer, MD
No financial relationships exist with ineligible companies.
Roman Bronfenbrener, MD, FAAD
No financial relationships exist with ineligible companies.
Kelly Flanagan, MS
No financial relationships exist with ineligible companies.
Elif Karatas, MD
No financial relationships exist with ineligible companies.
Richard A. Keller, MD, FAAD
AbbVie – Stockholder(Other Financial Benefit); American Academy of Dermatology – Other(No Compensation Received); American College of Mohs Surgery – Other(No Compensation Received); American Society of Dermatologic Surgery – Other(No Compensation Received); Association of Military Dermatologist – Other(No Compensation Received); Department of DEFENSE – Other(Salary); Department. of Veterans Affairs – Employee(Salary), Other(Salary); Gilead Sciences, Inc – Stockholder(Other Financial Benefit); Medtronics – Stockholder(Stock); Merck – Stockholder(Stock);
Rita Khodosh, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Joshua L. Owen, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Martina J. Porter, MD, FAAD
AbbVie – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Alumis – Consultant(Fees); AnaptysBio – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Bayer – Investigator(Grants/Research Funding); Beth Israel Deaconess Medical Center – Other(Patent royalties or other compensation for Intellectual Property Rights); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(No Compensation Received); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Consultant(Fees); Merck – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Mirador – Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Investigator(Grants/Research Funding); Oasis Pharmaceuticals – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Prometheus Laboratories, Inc. – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Trifecta Clinical – Consultant(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Zura Bio – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Anjani Sheth, MD, MPH
No financial relationships exist with ineligible companies.
Gideon Smith, MD, FAAD
No financial relationships exist with ineligible companies.
Nikki Trupiano, MD
No financial relationships exist with ineligible companies.
David Weiner, MD, MBE
No financial relationships exist with ineligible companies.
Albert Zhou, MD, PhD
No financial relationships exist with ineligible companies.